RTP Mobile Logo
Patterns of Care: Understanding and Optimizing the Current Management of Metastatic Prostate Cancer in the Real World (Audio Program)
Released October 2020

Featuring a roundtable discussion with Drs Andrew J Armstrong, Celestia S Higano, David F Penson and Neal D Shore. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

    LEARNING OBJECTIVES

    • Apply clinical research findings in the selection and sequencing of available local and systemic treatment modalities for patients with metastatic prostate cancer.
    • Evaluate the published research database supporting the use of cytotoxic and secondary hormonal therapy in the setting of metastatic hormone-sensitive prostate cancer (mHSPC) to design effective treatment plans for patients.
    • Recall the recent FDA approvals of enzalutamide and apalutamide for patients with mHSPC, and effectively integrate these agents into clinical practice.
    • Consider the adverse effects associated with hormonal agents commonly employed in the treatment of prostate cancer, and develop strategies to prevent, mitigate and manage these toxicities.
    • Explore available and emerging research data on the optimal management of metastatic castration-resistant prostate cancer, and apply recent advances to current clinical care.
    • Understand the rationale for genetic testing for BRCA1/2 and other mutations in patients with prostate cancer, and advise those found to harbor these genetic alterations about the FDA approvals and potential benefits of PARP inhibitors.
    • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 3.75 (audio) and 2.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/POCMetsProstate20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/POCMetsProstate20/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/POCMetsProstate20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/POCMetsProstate20.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Andrew J Armstrong, MD, ScM
    Professor of Medicine, Surgery, Pharmacology and Cancer Biology
    Director of Research
    Duke Cancer Institute Center for Prostate and Urologic Cancers
    Divisions of Medical Oncology and Urology
    Duke University
    Durham, North Carolina

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Merck, Pfizer Inc, Tolero Pharmaceuticals; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc.

    Celestia S Higano, MD
    Affiliate Professor, Department of Urologic Sciences
    University of British Columbia
    Director, Prostate Cancer Supportive Care Program
    Vancouver Prostate Centre
    Vancouver, British Columbia, Canada

    Consulting, Scientific Advisory Boards: Astellas, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Carrick Therapeutics, Clovis Oncology, Dendreon Pharmaceuticals Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Hinova Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Novartis, Orion Corporation, Pfizer Inc, Tolmar; Institutional Research Funding: Aptevo Therapeutics, Aragon Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Dendreon Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Emergent BioSolutions Inc, F Hoffman-La Roche Ltd, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Pfizer Inc; Other: Spouse holds stock and former officer of CTI BioPharma Corp.

    David F Penson, MD, MPH, MMHC
    Hamilton and Howd Chair in Urologic Oncology
    Professor and Chairman, Department of Urology
    Nashville, Tennessee

    No financial interests or affiliations to disclose.

    Neal D Shore, MD
    Medical Director
    Carolina Urologic Research Center
    Atlantic Urology Clinics
    Myrtle Beach, South Carolina

    Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Dendreon Pharmaceuticals Inc, FerGene, Ferring Pharmaceuticals, Foundation Medicine, Janssen Biotech Inc, MDxHealth, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Nymox Pharmaceutical Corporation, Pfizer Inc, Sanofi Genzyme, Tolmar; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Speakers Bureau: Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from Astellas and Pfizer Inc.

    Release date: October 2020
    Expiration date: October 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):

Optimizing the Choice of Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Selection and Sequencing of Therapies for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Select Publications